ProFound Therapeutics
Flagship Pioneering biotechnology company using proteomics and computation to discover previously unannotated proteins, drug targets, and biomarkers in maternal health.
What They Do
ProFound's ProFoundry platform combines protein-detection methods, computational analysis, and high-throughput experiments to map proteins outside the conventionally annotated human proteome. Its maternal-health work applies the platform and agentic AI to placental tissue and serum from women with preeclampsia and eclampsia. The company received a Gates Foundation commitment of up to $35M, including an initial $20M, for preeclampsia and eclampsia target and biomarker discovery.
Competitive Position
ProFound competes with proteomics and AI drug-discovery platforms such as Seer, Nautilus Biotechnology, and Generate:Biomedicines. In maternal health, the Gates-backed preeclampsia program is target and biomarker discovery rather than clinical monitoring or care delivery.
Funding Rounds
No funding rounds on record for this company.